Last reviewed · How we verify
NCT05971147
Time Course Change in Skeletal Muscle and Blood Phospholipid Composition With Omega-3 Fatty Acid Supplementation
NA trial testing Fish oil in Skeletal Muscle Fatty Acid Metabolism in 29 participants. Completed in 13 January 2025.
31 December 2024
Quick facts
| Lead sponsor | Dr. Chris McGlory, PhD |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 29 |
| Start date | 1 August 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 13 January 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Fish oil — full drug profile →
Conditions studied
- Skeletal Muscle Fatty Acid Metabolism — all drugs for Skeletal Muscle Fatty Acid Metabolism →
Sponsor
Dr. Chris McGlory, PhD
Who can join
Adults 19 to 30, any sex, with Skeletal Muscle Fatty Acid Metabolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Increased omega-3 fatty acid composition of human skeletal muscle phospholipids is linked to improved skeletal muscle strength and growth in women and men. However, what is unknown is if biological sex influences skeletal muscle phospholipid composition in response to omega-3 fatty acid supplementation. Moreover, whilst time course changes in skeletal muscle phospholipid composition with omega-3 fatty acid intake have been established, no study has characterized a washout of omega-3 fatty acids from skeletal muscle phospholipids following cessation of omega-3 fatty acid intake. Thus, the aim of the present investigation is to establish a time course change and washout of omega-3 fatty acids from skeletal muscle phospholipids in response to omega-3 fatty acid intake. The investigators also aim to establish if this washout is impacted by biological sex.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05971147
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fish oil
Trials testing the same drug.
- NCT06424860 — Fish Oil, Metformin and Heart Health in PCOS · Phase 1 · recruiting
- NCT05613803 — Poly-unsaturated Fats for Improving Nasal Polyps and Asthma · Phase 3 · unknown
- NCT05869526 — A Comparison of the Effects of Krill Oil and Fish Oil Supplementation on Muscle Function in Older Adults · NA · completed
- NCT05677074 — Do Patients With Fish or Shellfish Allergy Tolerate the Consumption of Fish Oil Supplements? A Clinical Study · NA · completed
- NCT04768595 — Study of the Effect of Different Fish Oils on Omega-3 Index (CetoIndex) · NA · unknown
Other Dr. Chris McGlory, PhD trials
Trials by the same sponsor.
- NCT06233825 — Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults · NA · completed
- NCT06137066 — The Effect of Green Coffee Extract on Blood Glucose Homeostasis in Healthy Adults · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05971147 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Chris McGlory, PhD
- Last refreshed: 29 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05971147.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing